Ketoconazole therapy of progressive coccidioidomycosis. Comparison of 400- and 800-mg doses and observations at higher doses

John N Galgiani, David A. Stevens, John R. Graybill, William E. Dismukes, Gretchen A. Cloud

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

One hundred and twelve patients with progressive pulmonary, skeletal, or soft tissue infections caused by Coccidioides immitis were randomly assigned to treatment with 400 or 800 mg per day dosages of ketoconazole. During therapy, if response was unsatisfactory, the protocol provided for treatment with higher doses. With 400 mg, ketoconazole resulted in 23.2 percent successes, which was similar to 32.1 percent successes with 800-mg treatments (p = 0.29). An additional six of 23 patients in whom initial therapy failed and who later received 1,200 or 1,600 mg per day of ketoconazole also showed improvement. However, among patients completing successful courses of therapy, relapses were more frequent in those requiring higher than 400-mg dosages for their success. From these studies, it is concluded that ketoconazole in doses above those currently recommended offer little or no benefit for most patients with non-meningeal forms of coccidioidomycosis.

Original languageEnglish (US)
Pages (from-to)603-610
Number of pages8
JournalAmerican Journal of Medicine
Volume84
Issue number3 PART 2
DOIs
StatePublished - 1988
Externally publishedYes

Fingerprint

Coccidioidomycosis
Ketoconazole
Coccidioides
Therapeutics
Soft Tissue Infections
Clinical Protocols
Recurrence
Lung

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Ketoconazole therapy of progressive coccidioidomycosis. Comparison of 400- and 800-mg doses and observations at higher doses. / Galgiani, John N; Stevens, David A.; Graybill, John R.; Dismukes, William E.; Cloud, Gretchen A.

In: American Journal of Medicine, Vol. 84, No. 3 PART 2, 1988, p. 603-610.

Research output: Contribution to journalArticle

Galgiani, John N ; Stevens, David A. ; Graybill, John R. ; Dismukes, William E. ; Cloud, Gretchen A. / Ketoconazole therapy of progressive coccidioidomycosis. Comparison of 400- and 800-mg doses and observations at higher doses. In: American Journal of Medicine. 1988 ; Vol. 84, No. 3 PART 2. pp. 603-610.
@article{ee38cb64e4ef42e0ace68b2d06f20b32,
title = "Ketoconazole therapy of progressive coccidioidomycosis. Comparison of 400- and 800-mg doses and observations at higher doses",
abstract = "One hundred and twelve patients with progressive pulmonary, skeletal, or soft tissue infections caused by Coccidioides immitis were randomly assigned to treatment with 400 or 800 mg per day dosages of ketoconazole. During therapy, if response was unsatisfactory, the protocol provided for treatment with higher doses. With 400 mg, ketoconazole resulted in 23.2 percent successes, which was similar to 32.1 percent successes with 800-mg treatments (p = 0.29). An additional six of 23 patients in whom initial therapy failed and who later received 1,200 or 1,600 mg per day of ketoconazole also showed improvement. However, among patients completing successful courses of therapy, relapses were more frequent in those requiring higher than 400-mg dosages for their success. From these studies, it is concluded that ketoconazole in doses above those currently recommended offer little or no benefit for most patients with non-meningeal forms of coccidioidomycosis.",
author = "Galgiani, {John N} and Stevens, {David A.} and Graybill, {John R.} and Dismukes, {William E.} and Cloud, {Gretchen A.}",
year = "1988",
doi = "10.1016/0002-9343(88)90143-X",
language = "English (US)",
volume = "84",
pages = "603--610",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "3 PART 2",

}

TY - JOUR

T1 - Ketoconazole therapy of progressive coccidioidomycosis. Comparison of 400- and 800-mg doses and observations at higher doses

AU - Galgiani, John N

AU - Stevens, David A.

AU - Graybill, John R.

AU - Dismukes, William E.

AU - Cloud, Gretchen A.

PY - 1988

Y1 - 1988

N2 - One hundred and twelve patients with progressive pulmonary, skeletal, or soft tissue infections caused by Coccidioides immitis were randomly assigned to treatment with 400 or 800 mg per day dosages of ketoconazole. During therapy, if response was unsatisfactory, the protocol provided for treatment with higher doses. With 400 mg, ketoconazole resulted in 23.2 percent successes, which was similar to 32.1 percent successes with 800-mg treatments (p = 0.29). An additional six of 23 patients in whom initial therapy failed and who later received 1,200 or 1,600 mg per day of ketoconazole also showed improvement. However, among patients completing successful courses of therapy, relapses were more frequent in those requiring higher than 400-mg dosages for their success. From these studies, it is concluded that ketoconazole in doses above those currently recommended offer little or no benefit for most patients with non-meningeal forms of coccidioidomycosis.

AB - One hundred and twelve patients with progressive pulmonary, skeletal, or soft tissue infections caused by Coccidioides immitis were randomly assigned to treatment with 400 or 800 mg per day dosages of ketoconazole. During therapy, if response was unsatisfactory, the protocol provided for treatment with higher doses. With 400 mg, ketoconazole resulted in 23.2 percent successes, which was similar to 32.1 percent successes with 800-mg treatments (p = 0.29). An additional six of 23 patients in whom initial therapy failed and who later received 1,200 or 1,600 mg per day of ketoconazole also showed improvement. However, among patients completing successful courses of therapy, relapses were more frequent in those requiring higher than 400-mg dosages for their success. From these studies, it is concluded that ketoconazole in doses above those currently recommended offer little or no benefit for most patients with non-meningeal forms of coccidioidomycosis.

UR - http://www.scopus.com/inward/record.url?scp=0023974406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023974406&partnerID=8YFLogxK

U2 - 10.1016/0002-9343(88)90143-X

DO - 10.1016/0002-9343(88)90143-X

M3 - Article

C2 - 3279775

AN - SCOPUS:0023974406

VL - 84

SP - 603

EP - 610

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 3 PART 2

ER -